step 1 trial semaglutide 2.4 mg weight loss nejm 2021 For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for management as a once-weekly subcutaneous injection. In a previous trial, oral at a dose of 50 Tirzepatide vs Semaglutide Compared |

95% CI, 0.68-0.98) and all-cause mortality (HR = 0.8

Side effects of the exenatide brands Exenatide shares the class side-effect profile, and nausea is reported particularly often with the twice-daily form: Nausea, most common when starting or after a dose increase Vomiting and diarrhea Reduced appetite Injection-site reactions, including small nodules that are more frequent with the extended-release product Pancreatitis is a labeled risk for the class

Variants like FTO rs9939609 appear in some patients and may provide clinical context when interpreted by a qualified healthcare provider, though genetic testing does not predict exact medication response

10.1136/gut.40.5.597 69